Considerations in Multiple Myeloma: Maintenance Therapy

Supplements
Download PDF
Sagar Lonial, MD
Elizabeth Bilotti, MSN, APRN, BC, OCN®
Jonathan Kaufman, MD
Timothy McGuire, PharmD, FCCP, BCOP

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: May 11th, 2009 - May 11th, 2010

This activity is no longer available for credit, however its content is still relevant for your educational needs.


Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with multiple myeloma (MM).

Target Audience
This activity was developed for physicians, nurses, and pharmacists.

Learning Objectives
At the completion of this activity participants should be able to:

  • Define the role of posttransplant maintenance therapy in the treatment of patients with multiple myeloma (MM)
  • Describe how novel agents for MM can be used to sustain response and possibly delay relapse in patients with MM
  • Interpret new data from clinical trials of maintenance regimens for MM as reported at the 2008 ASH annual meeting
  • Identify the risks and benefits associated with novel agents used in the maintenance setting, including increased toxicity and acquired drug resistance


Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:



Faculty Disclosures
*Sagar Lonial, MD, is a consultant for Bristol-Myers Squibb, Celgene, Millennium, and Novartis, and has received research support from Bristol-Myers Squibb, Celgene, Gloucester, Millennium, and Novartis.

Elizabeth Bilotti, MSN, APRN, BC, OCN® is on the speaker's bureau for Amgen, Celgene, and Pharmion.

*Jonathan Kaufman, MD, is a consultant for Celgene and Millennium.

Timothy McGuire, PharmD, FCCP, BCOP has received research support from AstraZeneca.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Related Items
Conference Faculty Perspectives: Highlights From ASCO 2010
Paul Richardson, MD, William Bensinger, MD, Kenneth C. Anderson, MD, Melissa Alsina, MD, Jonathan Kaufman, MD
Supplements published on August 13, 2010
Considerations in Multiple Myeloma: Case Studies in Front-line Therapy
Katherine Sanvidge Shah, PharmD, BCOP, Jonathan Kaufman, MD, Charise Gleason, MSN, ANP-BC, AOCNP, Nicole Wilson, PharmD, BCOP
Supplements published on February 17, 2010
Considerations in Multiple Myeloma: Sequencing Strategies
Sagar Lonial, MD, Ajai Chari, MD, Sidney V. Keisner, PharmD, Sachin R. Shah, PharmD, BCOP
Supplements published on November 16, 2009
Considerations in Multiple Myeloma: To Transplant or Not to Transplant...That Is the Question!
Sagar Lonial, MD, Joan Bladé, MD, Dareth N. Gilmore, MS, RN, CNP, Sandra Horowitz, PharmD, RPh
Supplements published on November 16, 2009
Considerations in Multiple Myeloma: Cytogenetic Testing
Sagar Lonial, MD, Steve Stricker, PharmD, MS
Supplements published on September 30, 2009
Recent Advances in the Treatment of Multiple Myeloma
Jonathan Kaufman, MD, Beth Faiman, RN, MSN, APRN, BC, AOCN, Stephanie S. Minich, PharmD, BCOP, James O. Armitage, MD
Supplements published on September 30, 2009
Considerations in Multiple Myeloma: Stem Cell Mobilization
Sagar Lonial, MD, William Bensinger, MD, Beth Faiman, RN, MSN, APRN, BC, AOCN
Supplements published on August 31, 2009
Considerations in Multiple Myeloma: Perspectives on Relevant End Points of Clinical Trials
Sagar Lonial, MD, Shaji Kumar, MD, Gail M. Sulski, RN, MS, FNP, AOCNP, Katherine Sanvidge Shah, PharmD, BCOP
Supplements published on July 14, 2009
Considerations in Multiple Myeloma: Do Complete Responses Correlate with Clinical Benefit?
Sagar Lonial, MD, Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC, Jill M. Kolesar, PharmD, FCCP, BCPS
Supplements published on June 10, 2009
Considerations in Multiple Myeloma: Retreatment Settings
Sagar Lonial, MD, Jeffrey Wolf, MD, Charise Gleason, MSN, ANP-BC, AOCNP, R. Donald Harvey, PharmD, FCCP, BCPS, BCOP
Supplements published on March 31, 2009
Last modified: March 24, 2014